Equity Profile

MIRM

Mirum Pharmaceuticals, Inc.

Health CareBiotechnology$7.3B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Investors will be looking for signs of revenue growth as it reflects the company's ability to expand its market presence and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MIRM Q2-2026 Earnings Preview

Context

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $7 billion, it operates in the health care sector, which is increasingly important as demand for specialized treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

In Q1-2026, Mirum reported an EPS of -$13.43, significantly missing estimates. Despite this, the stock rose by 4.04% the following day, indicating some investor optimism.

Management Promises & Guidance

Focus on advancing pipeline candidates.
Commitment to addressing operational challenges.
Plans to enhance market strategies for existing products.

Expectations

Wall Street Expectations

Investors are cautious but hopeful for a turnaround after a significant earnings miss last quarter. The upcoming report will be critical for assessing the company's trajectory.

Bull Case

If Mirum shows improved EPS and revenue growth, it could signal a recovery and boost investor confidence, leading to a strong stock performance.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, as investors may lose faith in the company's strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key pipeline candidates?

The market will closely watch for any delays or advancements, as these can significantly impact future revenue potential.

How does management plan to address the recent earnings miss?

Investors will want to hear concrete steps to improve financial performance and restore confidence in the company's strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Mirum to make significant progress in its pipeline, which could lead to a surprise in revenue growth.

Supporting Evidence

The options market is pricing in a 37.56% move, indicating high uncertainty that could lead to a larger reaction than expected.

Historical data shows that the stock has reacted positively to pipeline updates, suggesting potential for upside.

Key Risk

If the company can demonstrate a clear path to reducing EPS losses, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical in determining whether Mirum can stabilize its financial situation and regain investor confidence.

Bull Confirmed If

A reduction in EPS losses to below -$10 would indicate a positive shift in financial health.

Bear Confirmed If

If EPS remains worse than -$13, it could confirm ongoing operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±37.56%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±37.6% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

56.0%

Calls (10K)P/C Ratio: 3.33Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum exceeds expectations, history suggests a potential stock increase of around +1.33%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity.

Miss

Should the company report worse-than-expected results, history indicates a potential decline of around +0.31%, reinforcing bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key pipeline drugs and their expected timelines.
2Management's strategy for addressing the recent earnings miss.
3Any new partnerships or collaborations that could enhance growth.
4Insights into market reception of existing products.
5Guidance on future revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Investors will be looking for signs of revenue growth as it reflects the company's ability to expand its market presence and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MIRM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

In Q1-2026, Mirum reported an EPS of -$13.43, significantly missing estimates. Despite this, the stock rose by 4.04% the following day, indicating some investor optimism.

Management Promises & Guidance

Focus on advancing pipeline candidates.
Commitment to addressing operational challenges.
Plans to enhance market strategies for existing products.

Expectations

Wall Street Expectations

Investors are cautious but hopeful for a turnaround after a significant earnings miss last quarter. The upcoming report will be critical for assessing the company's trajectory.

Bull Case

If Mirum shows improved EPS and revenue growth, it could signal a recovery and boost investor confidence, leading to a strong stock performance.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, as investors may lose faith in the company's strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key pipeline candidates?

The market will closely watch for any delays or advancements, as these can significantly impact future revenue potential.

How does management plan to address the recent earnings miss?

Investors will want to hear concrete steps to improve financial performance and restore confidence in the company's strategy.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Mirum to make significant progress in its pipeline, which could lead to a surprise in revenue growth.

Supporting Evidence

The options market is pricing in a 37.56% move, indicating high uncertainty that could lead to a larger reaction than expected.

Historical data shows that the stock has reacted positively to pipeline updates, suggesting potential for upside.

Key Risk

If the company can demonstrate a clear path to reducing EPS losses, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical in determining whether Mirum can stabilize its financial situation and regain investor confidence.

Bull Confirmed If

A reduction in EPS losses to below -$10 would indicate a positive shift in financial health.

Bear Confirmed If

If EPS remains worse than -$13, it could confirm ongoing operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±37.56%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant potential move in either direction, indicating uncertainty about the upcoming earnings report.

Options are pricing ±37.6% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

56.0%

Calls (10K)P/C Ratio: 3.33Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum exceeds expectations, history suggests a potential stock increase of around +1.33%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity.

Miss

Should the company report worse-than-expected results, history indicates a potential decline of around +0.31%, reinforcing bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key pipeline drugs and their expected timelines.
2Management's strategy for addressing the recent earnings miss.
3Any new partnerships or collaborations that could enhance growth.
4Insights into market reception of existing products.
5Guidance on future revenue expectations.